Stock Detail
NEUROGESX INC
Biotechnology
NGSX @ Yahoo Finance | NGSX Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $1.07 | $1.10 | $0.02 | 1.90% | 0.00 | $1.05 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $1.06 | $1.03 | 23,950 | 32.1M | 77,943 | -0.41 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 1.14 | 1.11 | 1.07 | 1.04 | 1.00 |
Stock Profile
NeurogesX, Inc., a biopharmaceutical company, engages in the development and commercialization of novel pain management therapies. It primarily focuses on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP), and painful diabetic neuropathy (PDN). The company's lead product candidate NGX-4010 is a synthetic capsaicin-based topical patch to manage pain associated with peripheral neuropathic pain conditions, has completed two pivotal Phase 3 clinical trials in PHN and HIV-DSP. It is also developing NGX-1998, a non-patch liquid formulation of synthetic capsaicin, and an opioid analgesic for use in managing pain associated with other chronic pain conditions, such as cancer pain. The company was founded in 1998 as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in September 2000. NeurogesX is headquartered in San Carlos, California.